GRI Bio, Inc.

GRI BIO, INC. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for serious diseases associated with dysregulated immune responses, specifically inflammatory, fibrotic, and autoimmune disorders. The company's core business model revolves around advancing product candidates through preclinical and clinical development, with the ultimate goal of obtaining regulatory approval and commercializing these therapies. Revenue generation is currently absent, and the company has incurred significant net losses since inception, financing operations primarily through equity and debt offerings ¹. The primary customer segments, once products are approved, would be patients suffering from conditions like Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE).

The company's pipeline includes two main product candidates: GRI-0621 and GRI-0803, along with a proprietary library of over 500 compounds. GRI-0621 is an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells, being developed for severe fibrotic lung diseases such as Idiopathic Pulmonary Fibrosis (IPF). IPF affects approximately 140,000 people in the United States, with up to 40,000 new cases per year, and an estimated 3 million globally ². The active pharmaceutical ingredient in GRI-0621, tazarotene, is a synthetic retinoid acid receptor-beta and gamma selective agonist, which is approved for topical treatment of psoriasis and acne, and has been evaluated in over 1,700 patients as an oral product for up to 52 weeks ³. GRI-0803 is a novel oral agonist of type 2 diverse Natural Killer T (dNKT) cells, intended for the treatment of autoimmune disorders, with preclinical work focused on Systemic Lupus Erythematosus (SLE) and Multiple Sclerosis (MS) ⁴. SLE affects between 160,000 and 200,000 patients in the United States, with 80,000 to 100,000 suffering from kidney nephritis ⁵.

For the fiscal year ended December 31, 2025, GRI BIO, INC. reported total operating expenses of $11.977 million ⁶, comprising research and development expenses of $6.819 million ⁷ and general and administrative expenses of $5.158 million ⁸. The company recorded a loss from operations of $11.977 million ⁹. There was a change in the fair value of warrant liability, resulting in a decrease of $3,000 ¹⁰. Interest income for the period was $21,000 ¹¹. The net loss for the year ended December 31, 2025, was $11.956 million ¹². As of December 31, 2025, the company had cash and cash equivalents of $8.2 million ¹³ and an accumulated deficit of $51.7 million ¹⁴.

Comparing the fiscal year ended December 31, 2025, to the year ended December 31, 2024, research and development expenses increased by $3.0 million, from $3.768 million ¹⁵ in 2024 to $6.819 million ¹⁶ in 2025. This increase was primarily driven by a $2.9 million ¹⁷ rise in expenses related to the registration development program of GRI-0621, a $0.1 million ¹⁸ increase in personnel expense (including stock-based compensation), and a $0.1 million ¹⁹ increase in consulting fees. General and administrative expenses also increased by $0.7 million, from $4.467 million ²⁰ in 2024 to $5.158 million ²¹ in 2025, mainly due to a $0.7 million ²² increase in personnel costs, including stock-based compensation expense. The net loss widened from $8.207 million ²³ in 2024 to $11.956 million ²⁴ in 2025. Net cash used in operating activities increased from $8.611 million ²⁵ in 2024 to $10.186 million ²⁶ in 2025. Net cash provided by financing activities increased from $11.831 million ²⁷ in 2024 to $13.390 million ²⁸ in 2025.

During the reported period, GRI BIO, INC. completed a Phase 2a clinical trial for GRI-0621 in patients with IPF. Based on topline results, the trial met its primary endpoint of safety and tolerability, and secondary endpoints measured to date. No treatment-related serious adverse events were reported, with adverse events being Grade 2 (17%) or Grade 3 (4%) ²⁹. FVC was observed to increase by 99 ml in the GRI-0621-treated arm and by 139 ml in the subset taking both GRI-0621 and standard of care, compared to placebo plus standard of care ³⁰. A post hoc analysis, excluding outliers, showed an increase of 54 ml in the GRI-0621-treated arm and 81 ml in the subset taking both GRI-0621 and standard of care ³¹. The company also conducted several financing activities, including the December 2025 Offering, which generated net proceeds of $6.3 million ³², and the April 2025 Offering, which generated net proceeds of $4.0 million ³³. Additionally, the company sold 60,003 shares ³⁴ of common stock in an At The Market (ATM) Offering at a weighted-average price of $102.75 per share ³⁵, raising $6.2 million ³⁶ in gross proceeds and $5.9 million ³⁷ in net proceeds as of December 31, 2025. The company also effected a one-for-28 reverse stock split on January 23, 2026 ³⁸, reducing outstanding shares from 15,960,229 ³⁹ to 570,002 ⁴⁰.

GRI BIO, INC. has not provided formal revenue, margin, or EPS guidance for the upcoming period. However, the company has outlined its strategic priorities and operational plans.

The primary growth area for the company is the advancement of GRI-0621 in Idiopathic Pulmonary Fibrosis (IPF). Based on the positive topline results from the Phase 2a trial, the company plans to initiate a Phase 2b trial, either independently or with a strategic partner ⁴¹. This Phase 2b trial is envisioned to potentially support an application for conditional approval in the European Union and could be considered a registrational trial in the United States ⁴². The company believes GRI-0621 has the potential to be the first true disease-modifying therapy for IPF patients, an orphan disease that is therapeutically underserved ⁴³.

Another significant growth area is the development of GRI-0803 for autoimmune disorders, with an initial focus on Systemic Lupus Erythematosus (SLE). The company intends to complete IND-enabling studies and file an IND application to evaluate GRI-0803 in a Phase 1a and 1b trial in healthy volunteers in 2026 ⁴⁴. The initial focus for development would be lupus, and the company expects to continue evaluating other indications to select the best fit for further development ⁴⁵.

Regarding operational outlook, the company expects its research and development expenses to increase over the next several years as it conducts planned clinical and preclinical activities for its product candidates ⁴⁶. General and administrative expenses are also expected to continue to increase due to costs associated with being a public company, including compliance with Nasdaq and SEC requirements, directors' and officers' insurance, legal and accounting costs, investor relations, and an increase in personnel expenses ⁴⁷. The company relies on third-party contract manufacturers for its product candidates and a limited number of suppliers for raw materials, which could lead to supply chain disruptions or delays if these third parties fail to meet obligations or if alternative suppliers cannot be found on acceptable terms ⁴⁸.

The company's planned capital allocation strategy involves financing future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements, and other marketing or distribution arrangements ⁴⁹. As of December 31, 2025, the company had approximately $8.2 million ⁵⁰ in cash and cash equivalents and believes this will be sufficient to fund operating expenses and capital expenditure requirements into the first quarter of 2027 ⁵¹. However, this estimate assumes only the commencement of preliminary work towards the initiation of a Phase 2b trial of GRI-0621, and substantial additional capital or resources would be required to complete such a trial ⁵².

The company has identified structural headwinds and execution risks, including the need for substantial additional capital to finance operations and complete the Phase 2b clinical trial of GRI-0621 ⁵³. Management has expressed substantial doubt about the company's ability to continue as a going concern ⁵⁴. Delays in clinical development, regulatory issues, or problems with product candidates could significantly harm development plans ⁵⁵. The company also faces risks related to its reliance on third parties for clinical trials and manufacturing, and the potential for product liability lawsuits ⁵⁶. Furthermore, the company's internal controls were not effective as of December 31, 2025, due to a material weakness related to accounting software limitations and a limited number of accounting personnel, which could impair its ability to produce accurate financial statements ⁵⁷.

The company faces material risks related to its financial position, including significant net losses since inception and an accumulated deficit of $51.7 million ⁵⁸ as of December 31, 2025. There is substantial doubt about the company's ability to continue as a going concern, and it will require substantial additional capital to finance operations, particularly to complete a Phase 2b clinical trial of GRI-0621 ⁵⁹. The company's existing cash and cash equivalents of $8.2 million ⁶⁰ are only expected to fund operations into the first quarter of 2027 ⁶¹, assuming only preliminary work for the Phase 2b trial. Operational risks include the inherent uncertainty, length, complexity, and expense of clinical development, where preclinical and early-stage results may not be predictive of later-stage outcomes, and interim data may change ⁶². The company relies heavily on third parties for clinical trials and manufacturing, exposing it to risks of delays, non-compliance, or supply interruptions ⁶³. Intellectual property protection is critical and costly, with risks of patents being challenged, invalidated, or expiring before commercialization ⁶⁴. Regulatory risks include ongoing compliance obligations, potential changes in FDA guidance, and the possibility that product candidates may not achieve market acceptance or adequate reimbursement ⁶⁵. The company's internal controls over financial reporting were not effective as of December 31, 2025, due to a material weakness related to accounting software limitations and limited accounting personnel, which could impair its ability to produce accurate financial statements ⁶⁶. Geopolitical conflicts, such as those in Ukraine and the Middle East, and international trade policies, tariffs, or embargoes, could disrupt supply chains and delay preclinical studies and clinical trials ⁶⁷.

Management's message to shareholders emphasizes the company's commitment to becoming an industry leader in developing therapies for inflammatory, fibrotic, and autoimmune disorders by targeting dysregulated immune responses. They highlight the progress of their lead product candidate, GRI-0621, noting that its Phase 2a clinical trial in IPF patients met its primary and secondary endpoints evaluated to date, with no treatment-related serious adverse events reported and adverse events being Grade 2 (17%) or Grade 3 (4%) ⁶⁸. Based on these results, management plans to initiate a Phase 2b trial for GRI-0621, which could support conditional approval in the European Union and potentially be a registrational trial in the United States, subject to FDA clearance and obtaining requisite additional funding or resources ⁶⁹. A key strategic priority is to efficiently advance the clinical development of GRI-0621 in IPF, an orphan disease. Another strategic priority is to advance GRI-0803, a novel oral agonist of dNKT cells, through Phase 1a/1b studies, initially targeting SLE, with an IND application expected to be filed in 2026 ⁷⁰. Management also intends to leverage its understanding of NKT cells to evaluate additional product candidates and pursue business development opportunities to expand its portfolio. They aim to build a patient-focused company and maximize the commercial value of their product candidates, retaining worldwide development and commercial rights, while also considering strategic collaborations for commercialization in certain geographies or highly prevalent indications. Management acknowledges the significant net losses incurred, totaling $11.956 million ⁷¹ for the year ended December 31, 2025, and the need for substantial additional capital to fund operations, particularly to complete the Phase 2b clinical trial of GRI-0621, as existing cash and cash equivalents of $8.2 million ⁷² are only projected to fund operations into the first quarter of 2027 ⁷³.